Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Beer, M; Weidemann, F; Breunig, F; Knoll, A; Koeppe, S; Machann, W; Hahn, D; Wanner, C; Strotmann, J; Sandstede, J.
Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy
Am J Cardiol. 2006; 97(10):1515-1518
Doi: 10.1016/j.amjcard.2005.11.087
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- Beer Meinrad
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The present study evaluated the evolution of cardiac morphology, function, and late enhancement as a noninvasive marker of myocardial fibrosis, and their inter-relation during enzyme replacement therapy in patients with Fabry's disease using magnetic resonance imaging and color Doppler myocardial imaging. Late enhancement, which was present in up to 50% of patients, was associated with increased left ventricular mass, the failure of a significant regression of hypertrophy during enzyme replacement therapy, and worse segmental myocardial function. Late enhancement may predict the effect of enzyme replacement therapy on left ventricular mass and cardiac function.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Contrast Media -
- Echocardiography, Doppler -
- Fabry Disease - drug therapy Fabry Disease - physiopathology Fabry Disease - ultrasonography
- Female -
- Gadolinium DTPA - diagnostic use
- Humans -
- Magnetic Resonance Imaging -
- Male -
- Statistics, Nonparametric -
- Treatment Outcome -
- alpha-Galactosidase - therapeutic use